| Particulars (Rupees in Crores.) | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 |
|---|---|---|---|---|---|
Gross Sales | 708.46 | 681.85 | 641.92 | 590.62 | 560.01 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 708.46 | 681.85 | 641.92 | 590.62 | 560.01 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 16.52 | 27.85 | 11.06 | 14.95 | 16.53 |
Total Income | 724.98 | 709.7 | 652.98 | 605.57 | 576.54 |
Total Expenditure | 582.7 | 543.08 | 506.24 | 462.18 | 450.37 |
PBIDT | 142.27 | 166.61 | 146.74 | 143.39 | 126.17 |
Interest | 3.44 | 2.67 | 2.63 | 2.92 | 4.84 |
PBDT | 138.84 | 163.95 | 144.11 | 140.46 | 121.33 |
Depreciation | 22.74 | 20.69 | 19.51 | 20.44 | 21.06 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 24.28 | 38.01 | 36.29 | 30.01 | 30.74 |
Deferred Tax | 1.09 | 0.18 | -9.45 | 0.94 | -8.11 |
Reported Profit After Tax | 90.73 | 105.07 | 97.76 | 89.07 | 77.64 |
Minority Interest After NP | 0.18 | 0.5 | 1.04 | 0.32 | -0.65 |
Net Profit after Minority Interest | 90.55 | 104.56 | 96.72 | 88.75 | 78.29 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 90.55 | 104.56 | 96.72 | 88.75 | 78.29 |
EPS (Unit Curr.) | 2 | 2.31 | 2.13 | 1.96 | 1.73 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 45.32 | 45.32 | 45.32 | 45.32 | 45.32 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 20.08 | 24.43 | 22.85 | 24.27 | 22.52 |
PBDTM(%) | 19.59 | 24.04 | 22.44 | 23.78 | 21.66 |
PATM(%) | 12.8 | 15.4 | 15.22 | 15.08 | 13.86 |
Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
